DUBLIN, Ireland, Jan. 16, 2009 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals (IEX:MERR) and Novo Nordisk A/S (NYSE:NVO - News), a world leader in diabetes, have entered into a Development and License Agreement to develop and commercialise oral formulations of a Novo Nordisk proprietary GLP-1 receptor agonist, using Merrion's proprietary GIPET(r) technology. This is the second license agreement between the two companies concerning Merrion's GIPET(r) technology -- the first agreement for the development of oral insulin analogues was signed in November 2008.
